Hydroxyzine

CHEMBL896 Phase 4 معتمد Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

374.9 g/mol

LogP

3.7

Phase

4

This first-generation antihistamine has anxiolytic, antipruritic, and sedative properties and is used to treat anxiety, itching from allergic conditions, and nausea. It works by blocking histamine H1 receptors and also affects other neurotransmitter systems in the brain. It does not carry the risk of dependence seen with benzodiazepines.

الوزن الجزيئي

374,9000 g/mol

LogP

3,70

TPSA

35,90 Å²

قاعدة ليبينسكي للخمسة

ناجح

المجالات العلاجية

Ovarian Cancer Pain Management Non-Small Cell Lung Cancer Asthma Migraine Schizophrenia Generalized Anxiety Disorder Oncology Multiple Sclerosis Type 2 Diabetes Major Depressive Disorder Breast Cancer Atopic Dermatitis Chronic Pain Colorectal Cancer

آلية العمل

Enhances the effect of gamma-aminobutyric acid (GABA) at GABA-A receptors by binding to an allosteric site and increasing the frequency of chloride ion channel opening. This produces anxiolytic, sedative, hypnotic, and anticonvulsant effects.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

الآلية

Enhances the effect of gamma-aminobutyric acid (GABA) at GABA-A receptors by binding to an allosteric site and increasing the frequency of chloride ion channel opening. This produces anxiolytic, sedative, hypnotic, …

البنية ثنائية الأبعاد

SVG PNG

Cite this structure

Embed this structure

SMILES

OCCOCCN1CCN(C(c2ccccc2)c2ccc(Cl)cc2)CC1

InChI

InChI=1S/C21H27ClN2O2/c22-20-8-6-19(7-9-20)21(18-4-2-1-3-5-18)24-12-10-23(11-13-24)14-16-26-17-15-25/h1-9,21,25H,10-17H2

Molecular Formula

C21H27ClN2O2

HBD / HBA

1 / 4

الروابط القابلة للدوران

8

الذرات الثقيلة

26

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

الأسئلة الشائعة

This first-generation antihistamine has anxiolytic, antipruritic, and sedative properties and is used to treat anxiety, itching from allergic conditions, and nausea. It works by blocking histamine H1 receptors and also affects other neurotransmitter systems in the brain. It does not carry the risk of dependence seen with benzodiazepines.

Enhances the effect of gamma-aminobutyric acid (GABA) at GABA-A receptors by binding to an allosteric site and increasing the frequency of chloride ion channel opening. This produces anxiolytic, sedative, hypnotic, and anticonvulsant effects.

Yes, Hydroxyzine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL896. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 3658. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

PillFYI

هل تبحث عن معلومات ملائمة للمرضى؟

Hydroxyzine على PillFYI

البنية

بيانات سريعة

الصيغة الجزيئية: C21H27ClN2O2
المرادفات: 4

روابط خارجية

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

إخلاء المسؤولية الطبية

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.